医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sorin Group Receives Regulatory Approval for New Generation MRI Compatible Pacing System in Japan

2015年02月06日 PM04:30
このエントリーをはてなブックマークに追加


 

TOKYO

Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today that it has received approval from Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for its new KORA 100 pacing system with automatic magnetic resonance imaging mode (MRI mode) .

Pacemakers are usually implanted in elderly patients, a population prone to other medical conditions that typically require MRI examinations for optimal diagnosis and management. KORA 100 SR and DR pacemakers, when implanted with the Sorin BEFLEX pacing lead(s) 1, enable implanted patients to safely undergo an MRI scan.

During an MRI scan pacemakers need to operate in asynchronous mode which exposes the patient to potential cardiac arrhythmias. This mode usually needs to be programmed by a cardiologist prior to and after the MRI scan which leaves the patient in asynchronous mode for a longer period of time than required by the MRI scan itself2.

Unlike other pacemakers, KORA 100 ensures that asynchronous mode is activated for the least amount of time. Once Auto MRI mode is activated, the KORA 100 automatically adjusts its settings when the MRI field is detected. This ensures the safe operation of the device during an MRI scan. The device senses when a patient leaves the magnetic field and returns to its initial operating mode within five minutes. The Automatic MRI mode feature is patented and available exclusively in Sorin Group pacemakers2.

The KORA 100 pacing system builds on Sorin’s legacy of proactively managing common cardiovascular comorbidities. The clinical results of the ANSWER study3 demonstrate that the SafeRTM 4 pacing mode results in a 51% risk reduction of cardiac death or HF hospitalization3. Moreover, the recently introduced Sleep Apnea Monitoring (SAM) function, a clinically validated5 diagnostic tool, allows for screening severe sleep apnea which is a significant comorbidity and risk factor related to heart failure and atrial fibrillation.

“The regulatory approval of our next-generation pacemaker marks a significant milestone for Sorin Group in Japan where there is strong demand for MRI compatible medical devices. We believe that KORA 100 with its unique automatic MRI mode, combination of therapeutic solutions, small size and extended longevity6, will bring proven benefits to Japanese patients and physicians. Leveraging on our collaboration with our established business partner, Japan Lifeline, we will be able to achieve our market objectives and reinforce our leadership position,” said Stefano Di Lullo, Sorin Group, President CRM Business Unit.

The KORA 100 pacing system will be distributed in Japan by Japan Lifeline Co., Ltd.

About Sorin Group

Sorin Group (www.sorin.com) is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,500 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators and non-invasive monitoring to diagnose and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.

For more information, please visit www.sorin.com

References

1. BEFLEX models RF45D (52 cm) and RF46D (58 cm).

2. SORIN MRI Solutions implant manual.

3. Stockburger M. et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.
European Heart Journal 2014; doi:10.1093/eurheartj/ehu336ANSWER Study

4. Available on KORA 100 DR

5. Defaye P. et al. A pacemaker transthoracic impedance sensor with an advanced algorithm to identify severe sleep apnea: The DREAM European study.
Heart Rhythm 2014; 11:842-848

6. Benkemoun H. et al. Optimizing pacemaker longevity with pacing mode and settings programming: results from a pacemaker multicenter registry.
Pacing Clin Electrophysiol 2012;35(4):403–8

CONTACT

Sorin Group
Gabriele Mazzoletti, +39 02 69 96 97 85
Director,
Corporate Communications
Mobile: +39 348 979 22 01
corporate.communications@sorin.com
or
Francesca
Rambaudi,
+39 02 69969716
Director, Investor Relations
investor.relations@sorin.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表